NGS-based RNA-sequencing market seen topping $11 billion by 2030

The global NGS-based RNA-sequencing market is projected to surpass $11 billion by 2030, with Asia-Pacific and the U.S. leading growth. The forecast points to rising demand from precision medicine, cancer research, and faster adoption of sequencing platforms in research and clinical labs.

Why it matters: - NGS-based RNA-sequencing is moving from a research tool into a broader clinical and diagnostics market. - The segment is projected to exceed $11 billion by 2030, showing how transcriptomics is becoming central to precision medicine, oncology, and genetic disease research. - Growth in this market also signals demand for sequencing platforms, consumables, bioinformatics, and lab automation.

What happened: - The Business Research Company published its NGS-Based RNA-Sequencing Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on October 26, 2026. - The report projects the NGS-based RNA-sequencing market will top $11 billion by 2030. - The broader next-generation sequencing market is expected to reach close to $28 billion by 2030. - RNA sequencing is projected to account for about 40% of that broader market. - The market is forecast to grow at a 22% compound annual growth rate through 2030. - A free sample of the market report is available. - The full market report is also available online.

The details: - Asia-Pacific is projected to be the largest regional market by 2030 at $3.7 billion. - Asia-Pacific market value is expected to rise from $1.3 billion in 2025 at a 23% CAGR. - The U.S. is forecast to remain the largest single-country market in 2030 at $3.2 billion. - The U.S. market is projected to grow from $1.2 billion in 2025 at a 22% CAGR. - Sequencing platforms and consumables are expected to be the largest product and service segment, at about 50% of the market or $6 billion by 2030. - The report includes sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing as key technology types. - The main application areas are expression profiling analysis, small RNA sequencing, and de novo transcriptome assembly. - Primary end users include research and academic institutions, pharmaceutical companies, biotechnology companies, and other specialized users. - The report says sample preparation products, sequencing platforms and consumables, sequencing services, and data analysis, storage, and management together are expected to generate more than $7.7 billion by 2030. - From 2025 to 2030, sample preparation products are projected to grow by $1 billion, sequencing platforms and consumables by $4 billion, sequencing services by $1 billion, data analysis by $1 billion, storage by $0.4 billion, and management by $0.3 billion. - Illumina Inc. held a 6% share of the global market in 2025. - The report lists Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Agilent Technologies Inc., Eurofins Scientific SE, BGI Group, Novogene Corporation, Oxford Nanopore Technologies Ltd., Bio-Rad Laboratories Inc., and GENEWIZ Inc. among the key players. - The market was described as fairly fragmented, with the top 10 players accounting for 18% of revenue in 2025. - Major raw material suppliers named in the report include Merck KGaA, Danaher Corporation, New England Biolabs, Promega Corporation, Cytiva, and TriLink BioTechnologies. - Notable wholesalers and distributors include Avantor Inc., Fisher Scientific, VWR International, Thomas Scientific, and Cole-Parmer Instrument Company. - The report identifies major end users such as Mayo Clinic, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Broad Institute, Wellcome Sanger Institute, and Genomics England.

Between the lines: - The forecast suggests transcriptomics is becoming more embedded in routine research and clinical workflows, not just specialized genomic studies. - Market concentration remains low enough for multiple vendors to compete, but technology depth and bioinformatics integration still create high barriers to entry. - The strongest opportunities appear to be shifting toward workflow automation, data analysis, and multi-omics compatibility rather than sequencing hardware alone. - The report’s emphasis on AI-driven analysis, single-cell RNA sequencing, and long-read capabilities points to a market where software and interpretation matter as much as sequencing output.

What's next: - Market expansion will likely track adoption of precision medicine, oncology research, and genetic disease testing. - Further growth may come from more automated library preparation, better transcript isoform detection, and improved sequencing accuracy. - Companies are expected to keep investing in AI, single-cell workflows, and clinical genomics partnerships to defend share. - Lexogen GmbH introduced the miRVEL profiling small RNA-Seq library preparation kit in October 2025, reflecting continued product development in small RNA workflows.

The bottom line: - NGS-based RNA-sequencing is set for sustained double-digit growth through 2030, led by clinical adoption, research spending, and expanding use cases across transcriptomics.